ReviewFrontiers in cell and developmental biology2016
Induced Pluripotent Stem Cells for Traumatic Spinal Cord Injury.
Review in Frontiers in cell and developmental biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Fighting for recovery on multiple fronts: The past, present, and future of clinical trials for spinal cord injury.Frontiers in cellular neuroscience · 2022Pooled it
- Evaluation of the Clinical Efficacy of Stem Cell Transplantation in the Treatment of Spinal Cord Injury: A Systematic Review and Meta-analysis.Cell transplantationPooled it
- Regenerative Medicine Strategies for Spinal Cord Injury: Advances in Stem Cell Therapy.Brain sciences · 2026Review
- 3D-Printed Scaffolds Promote Enhanced Spinal Organoid Formation for Use in Spinal Cord Injury.Advanced healthcare materials · 2025Article
- Assessment of immune modulation strategies to enhance survival and integration of human neural progenitor cells in rodent models of spinal cord injury.Stem cells translational medicine · 2025Review
- Transplantation of fibrin-thrombin encapsulated human induced neural stem cells promotes functional recovery of spinal cord injury rats through modulation of the microenvironment.Neural regeneration research · 2024Article
- Microarray analysis of lncRNAs and mRNAs in spinal cord contusion rats with iPSC-derived A2B5Heliyon · 2024Article
- Modern advances in spinal cord regeneration: hydrogel combined with neural stem cells.Frontiers in pharmacology · 2024Review
- Schwann Cell-Derived Exosomal Vesicles: A Promising Therapy for the Injured Spinal Cord.International journal of molecular sciences · 2023Review
- Longitudinal multiparametric MRI of traumatic spinal cord injury in animal models.Magnetic resonance imaging · 2023Review
- Neuroplasticity and regeneration after spinal cord injury.North American Spine Society journal · 2023Article
- Pediatric Spinal Cord Injury: A Review.Children (Basel, Switzerland) · 2023Review
- [Chemical reprogramming of human embryonic fibroblasts into neural progenitor cellsNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2023Article
- Review
- Progression in translational research on spinal cord injury based on microenvironment imbalance.Bone research · 2022Review
- scREMOTE: Using multimodal single cell data to predict regulatory gene relationships and to build a computational cell reprogramming model.NAR genomics and bioinformatics · 2022Article
- An Overview on Promising Somatic Cell Sources Utilized for the Efficient Generation of Induced Pluripotent Stem Cells.Stem cell reviews and reports · 2021Review
- Current Concepts of Stem Cell Therapy for Chronic Spinal Cord Injury.International journal of molecular sciences · 2021Review
- Organ-on-a-Chip systems for new drugs development.ADMET & DMPK · 2021Review
- The leading edge: Emerging neuroprotective and neuroregenerative cell-based therapies for spinal cord injury.Stem cells translational medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spinal cord injury (SCI) is a common cause of mortality and neurological morbidity. Although progress had been made in the last decades in medical, surgical, and rehabilitation treatments for SCI, the outcomes of these approaches are not yet ideal. The use of cell transplantation as a therapeutic strategy for the treatment of SCI is very promising. Cell therapies for the treatment of SCI are limited by several translational road blocks, including ethical concerns in relation to cell sources. The use of iPSCs is particularly attractive, given that they provide an autologous cell source and avoid the ethical and moral considerations of other stem cell sources. In addition, different cell types, that are applicable to SCI, can be created from iPSCs. Common cell sources used for reprogramming are skin fibroblasts, keratinocytes, melanocytes, CD34+ cells, cord blood cells and adipose stem cells. Different cell types have different genetic and epigenetic considerations that affect their reprogramming efficiencies. Furthermore, in SCI the iPSCs can be differentiated to neural precursor cells, neural crest cells, neurons, oligodendrocytes, astrocytes, and even mesenchymal stromal cells. These can produce functional recovery by replacing lost cells and/or modulating the lesion microenvironment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.